苑东生物(688513) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥274,735,003.12, representing a year-on-year increase of 15.53%[7] - The net profit attributable to shareholders for Q3 2021 was ¥68,732,494.54, showing a significant increase of 77.22% compared to the same period last year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥31,691,075.23, with an increase of 8.87% year-on-year[7] - The basic earnings per share for Q3 2021 was ¥0.57, up 46.15% compared to the same period last year[10] - Total operating revenue for the first three quarters of 2021 reached ¥773,436,181.18, an increase of 14.93% compared to ¥672,755,703.53 in the same period of 2020[35] - Net profit for the third quarter of 2021 was ¥186,075,903.15, up 48.82% from ¥124,861,472.73 in the third quarter of 2020[38] - Earnings per share for the third quarter were ¥1.55, compared to ¥1.34 in the same quarter of the previous year, reflecting a growth of 15.66%[40] - The company reported a significant increase in investment income to ¥14,453,402.64, compared to ¥3,811,178.13 in the previous year, marking a growth of 278.66%[38] Assets and Liabilities - The total assets at the end of the reporting period reached ¥2,740,283,925.73, reflecting an increase of 8.27% from the end of the previous year[10] - The company reported a total asset increase to CNY 2,740,283,925.73 as of September 30, 2021, up from CNY 2,530,857,158.85 at the end of 2020, representing an increase of approximately 8.26%[25] - Total liabilities amounted to ¥493,882,030.49, compared to ¥435,609,899.90 in the previous reporting period, reflecting an increase of 13.33%[34] - The company's total assets reached ¥2,740,283,925.73, up from ¥2,530,857,158.85, indicating a growth of 8.26%[34] - The company’s total current liabilities decreased significantly, with short-term borrowings reported at CNY 40,028,171.23 as of September 30, 2021[30] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥144,363,177.82, representing a substantial increase of 91.46% year-on-year[10] - Cash flow from operating activities was ¥815,557,529.00, an increase from ¥690,920,875.31 in the same period last year, showing a growth of 18.06%[42] - Cash received from operating activities totaled $909,989,358.80, an increase from $745,953,906.44[46] - Cash received from other operating activities was $75,577,372.28, compared to $49,226,830.50 last year[46] - Net cash flow from operating activities increased to $144,363,177.82, up from $75,402,330.31 year-over-year[46] Research and Development - Research and development expenses totaled ¥53,531,673.35 for the quarter, accounting for 19.48% of operating revenue, which is an increase of 1.08 percentage points year-on-year[10] - Research and development expenses increased to ¥147,822,178.55, representing a rise of 34.76% from ¥109,608,757.89 in the previous year[35] - The company has made significant progress in its drug development pipeline, with the phase II clinical trial of the drug Yogerletin showing effective control of HbA1c levels in patients with type 2 diabetes[20] - The company received approval for the clinical trial of EP-9001A injection, a novel monoclonal antibody drug targeting human nerve growth factor, indicating advancement in its oncology product line[21] Government Support and Investments - The company received government subsidies amounting to ¥42,496,440.88 during the quarter, contributing to the increase in net profit[11] - The company plans to change the use of CNY 61 million of unutilized fundraising for the marketing network construction project to increase capital for its wholly-owned subsidiary, ShuoDe Pharmaceutical[24] Inventory and Receivables - The company’s inventory increased to CNY 89,850,571.76 from CNY 84,029,013.29, reflecting a growth of approximately 6.67%[29] - The company’s receivables increased slightly, with accounts receivable at CNY 123,921,003.60 compared to CNY 121,298,288.19, showing a growth of about 2.15%[29] Cash and Cash Equivalents - Cash and cash equivalents decreased to CNY 210,384,310.95 from CNY 1,055,289,158.05, indicating a significant reduction of about 80.17%[25] - The company's cash and cash equivalents at the end of the period stood at $179,999,752.81, down from $1,412,759,103.07[48]